Key Takeaways
- Turnaround quarter, guidance on track: Revenue grew 9% YoY on volume, contribution margin jumped ~1,400 bps, and EBITDA rose 4x to INR2,163 crores, keeping the company confident of hitting its 50% EBITDA growth target for the year.
- The destocking overhang is gone: Channel inventories are largely normalized across major markets, resetting farmer and dealer buying patterns and restoring a healthy balance between sell-in and farm-gate demand.
- Margin reset looks durable, not a spike: The 19.8% EBITDA margin was built on structural COGS improvement, a richer differentiated/sustainable mix, and a permanently lower SG&A base, not on fleeting price gains.
- The balance sheet is healing fast: Working capital fell by INR6,000 crores YoY, gross debt dropped US$815 million, and net debt declined sequentially in a December quarter for the first time in recent memory.
- What to watch next quarter: Whether the Q3 margin level holds in Q4 as promised, the decision on calling or repricing perpetual bonds, and any update on FY26 volume and capex at the May Capital Markets Day.
Demand & Channel Recovery
- Destocking is complete in most regions: Management believes the multi-quarter channel destocking cycle has largely ended, with dealer purchases now balanced against farmer sales; only isolated exceptions remain, tied to local price timing or seasonality.
- Volume-led growth with stable pricing: The 9% volume growth was the primary revenue driver, while reported price gains of 5% came mostly from rebate normalization and the elimination of high-cost inventory, not from underlying product price increases.
- Post-patent prices have found a floor: Prices in the post-patent segment reset over 12 months ago and are now relatively stable; the differentiated and sustainable segment is seeing margin expansion from COGS efficiency, not price hikes.
- Competitive intensity remains high everywhere: Management acknowledged fierce competition in every market, not just Latin America, but argued UPL is growing volumes faster than the industry through its customer engagement model and platforms like Origeo with Bunge.
Mike Frank: "we believe that for the most part, in most regions, the destocking has been complete. And there's a good balance between what dealers and distributors are buying and what they're selling them to the farmers."
Margin Structure & Sustainability
- The 1,400 bps contribution margin jump was structural: The improvement to 41% was driven by a better product mix skewed toward differentiated and sustainable products, overall COGS reduction, and the normalization of rebates that had depressed prior-year margins.
- SG&A has been reset to a new, lower baseline: Management stated the current SG&A run rate reflects 18 months of restructuring and should persist going forward, though the company continues to hunt for incremental efficiency via AI tools.
- Employee costs are now at a benchmark level: The reduction in employee costs resulted from operational restructuring, and the Q3 level was described as a good benchmark for future quarters.
- Management calls this margin profile the new normal: The Q3 margin level is considered sustainable, with upside from new product launches in the differentiated and sustainable segment, which carry a higher margin profile than the corporate average.
- Raw material and China export prices are assumed flat: The base-case planning scenario assumes no change in export prices out of China, though management noted that selling at or around cost of goods is not a sustainable scenario for Chinese producers over the long term.
Mike Frank: "we really believe that this is the margin profile going forward with the opportunity as we think about the next 12 and 24 months to continue to drive our new product launches, which are primarily in the differentiated and sustainable segment, which we know has a higher overall margin profile."
Regional Performance
| Region | Trend | Commentary |
|---|---|---|
| North America | ▲ Strong growth | Revenue up 67% on strong demand, normalized channel inventories and rebates, and good s-metolachlor herbicide volumes. |
| Europe | ▲ Strong growth | Revenue up 23% driven by strong fungicide volumes (Proxanil®) and NPP products, with margin expansion. |
| Latin America | ▲ Solid growth | Revenue up 12% led by higher volumes of mancozeb and acephate-based products, partially offset by forex impact in Brazil; Evolution® and Feroce® improved differentiated volumes. |
| Rest of World | ▼ Decline | Revenue down 4% from pricing pressure in Africa, Australia and China; dollar-terms decline was less severe than the INR-terms drop. |
| UPL SAS (India) | ▲ Recovery | Revenue up 44% YoY on higher volumes, conscious placement closer to season, and lower Kharif returns; contribution margin improved 530 bps to 16.9%; EBITDA still marginally negative but improved sharply. |
| Advanta Seeds | ▬ Mixed | Revenue up 11% on higher volumes and better pricing, but margins contracted 615 bps on unfavorable crop mix and lower recoveries from higher input costs; EBITDA down 15%. |
Balance Sheet & Cash Flow
- Working capital turned a corner: Inventory days fell by 31 to 109, receivables days fell by 24 to 109, and non-recourse factoring was reduced by INR1,726 crores; the INR6,000 crore YoY working capital release was described as sustainable with further opportunity on DSOs.
- Debt reduction accelerated: Gross debt fell US$815 million YoY and net debt fell US$745 million; the December quarter saw net debt decline sequentially, a first in the recent period.
- Net debt-to-EBITDA is heading below 2x: Management is targeting a ratio below 2x, with an expectation to remain between 1.5x and 2x, or possibly below 1.5x.
- Interest costs have a tailwind: Hedging costs fell as interest rate differentials narrowed; natural hedges in Brazil, lower hedging costs in Argentina and Turkey, and rupee-denominated sales in Russia all contributed.
- The Advanta stake sale will bring further deleveraging: The US$350 million deal with Alpha Wave Global includes US$250 million in secondary proceeds to UPL earmarked for debt repayment, pending CCI clearance expected by mid-March.
- Bank covenants were renegotiated with a ratchet: Lenders agreed to a 35–40 bps spread increase, but with a condition that if net debt/EBITDA falls below 2x by March 2025 results, the increase will be rolled back.
Anand Vora: "This is for the first time in the recent period where our December net debt was lower than that of the previous quarter."
Product Portfolio & Innovation
- Differentiated and sustainable is the margin engine: This segment is driving mix improvement, COGS efficiency, and volume growth; new product launches are heavily skewed toward it, and it carries a structurally higher margin profile than the post-patent portfolio.
- New product launches are on track: The company expects to deliver approximately US$85 million from new product launches in FY25, with more coming next year and beyond.
- Nimaxxa® is expanding geographically: The 3-way fungicide for nematode control, already successful in Brazil, is now registered in the U.S. and commercializing in North America.
- Corteva Dithane® brand acquisition was included in year-to-date capex spend, adding to the fungicide portfolio.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA growth | Deliver 50% growth in EBITDA for the full year | FY25 |
| Operating free cash flow | Generate US$300–400 million of operating FCF | FY25 |
| Net debt-to-EBITDA | Reduce to below 2x, with a range of 1.5x–2x or possibly below 1.5x | FY25 exit |
| Q4 margins | Sustain strong margins similar to Q3, driven by differentiated/sustainable mix | Q4 FY25 |
| Capex | Maintain US$250–300 million range; FY25 spend expected below budget at INR1,500–1,600 crores | FY25 and beyond |
| Interest cost reduction | At least 1.0%–1.25% reduction in SOFR during the calendar year; spreads to improve 35–50 bps | Mid-July to August 2025 for spreads |
| Bank covenant ratchet | If net debt/EBITDA falls below 2x by March 2025 results, the 35–40 bps spread increase will be rolled back | March 2025 results |
| Advanta stake sale close | CCI clearance expected; proceeds for debt repayment | End of February to mid-March 2025 |
| Rights issue second call | First call of INR844 crores approved January 24, record date January 30 | Expected by end of March 2025 |
| Capital Markets Day | Provide more color on FY26 and beyond business evolution | May 2025 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹10,907 cr, +10% YoY; led by 9% volume growth, 5% pricing, offset by 4% forex |
| Contribution margin | 41.0%, ~1,400 bps jump YoY driven by product mix, COGS improvement, rebate normalization |
| EBITDA | ₹2,163 cr, 4x increase vs ₹416 cr in Q3 last year |
| EBITDA margin | 19.8%, ~1,600 bps increase from 4.2% YoY |
| Adjusted PAT | ₹828 cr vs loss of ₹1,217 cr in Q3 last year |
| Finance costs | ₹704 cr, marginally lower YoY due to drop in working capital and borrowings |
| Forex losses | ₹108 cr, sharp reduction from ₹613 cr in Q3 last year (which included Argentina devaluation) |
| Tax credit | ₹499 cr vs ₹59 cr last year; ₹592 cr provision reversed on favorable CIT(A) order for AY 2016-17 |
| 9-month revenue | ₹31,064 cr, +7% YoY; volumes +14%, price -5%, forex -2% |
| 9-month EBITDA | ₹4,884 cr, +36% YoY; margins at 15.7%, up 340 bps |
| Full-year EBITDA growth guidance | 50% growth over previous year, maintained |
| Net working capital days | 107 days, reduction of 48 days YoY from 155 days |
| Gross debt | US$3.53 bn (₹30,244 cr), reduced by US$815 mn YoY |
| Net debt reduction | US$745 mn lower vs same period last year; US$264 mn lower vs September |
| Operating free cash flow guidance | US$300 mn to US$400 mn for full year, maintained |
| Net debt-to-EBITDA target | ~2x for full financial year FY25 |
| Global crop protection revenue growth | +15% YoY, led by higher volumes in Latin America and Europe |
| Differentiated and sustainable volume growth | +16% YoY |
| Latin America revenue growth | +12% YoY, led by higher volumes offset by forex impact in Brazil |
| North America revenue growth | +67% YoY, strong demand with channel inventories and rebates normalized |
| Europe revenue growth | +23% YoY, driven by strong fungicide volumes and NPP products |
| Rest of World revenue growth | -4% YoY, primarily from pricing pressure in Africa, Australia, China |
| New product launches revenue target | US$85 mn expected for FY25 |
| UPL SAS (India CP) revenue | ₹535 cr, +44% YoY driven by higher volumes |
| UPL SAS EBITDA | Negative ₹24 cr vs negative ₹70 cr last year |
| Advanta Seeds revenue growth | +11% YoY, supported by higher volumes, better pricing, favorable FX |
| Advanta Seeds EBITDA | ₹223 cr, down 15% YoY due to lower contribution margin and strategic R&D, marketing investments |
| Capex spent YTD | ₹1,200 cr (includes Corteva Dithane® acquisition); full-year expected ₹1,500–₹1,600 cr vs ₹1,800 cr budget |
| Cost of debt | ~7% average across all debt instruments |
| Rights issue proceeds received | US$100 mn (₹844 cr) in Dec 2024; first call of another US$100 mn expected by March 2025 |
| Advanta stake sale proceeds | US$350 mn total (US$100 mn primary, US$250 mn secondary for UPL debt repayment), expected within FY25 |